Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients

Christoph Heesen*, Ingo Kleiter, Sven G. Meuth, Julia Krämer, Jürgen Kasper, Sascha Köpke, Wolfgang Gaissmaier

*Corresponding author for this work
8 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients'. Together they form a unique fingerprint.

Neuroscience